Text Size

SPECT/CT in Endocrine and Neuroendocrine Tumors

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00230139
First received: September 29, 2005
Last updated: October 11, 2008
Last verified: September 2005
History of Changes
  Purpose

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.


Condition Intervention
Endocrine and Neuroendocrine Tumors
 Device: SPECT/CT

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The impact of imaging modality on patient management [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The impact of imaging modality on patient management [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: January 2002
Study Completion Date: January 2006
Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)
Detailed Description:

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
  • Patient signed informed consent

Exclusion Criteria:

  • The study will not be performed in pregnant or lactating women.
  • Patient will not be able or willing to tolerate the scan until its completion.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00230139

Locations
Israel
Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Zohar Keidar, MD,PhD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00230139     History of Changes
Other Study ID Numbers: endocrineCTIL
Study First Received: September 29, 2005
Last Updated: October 11, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on June 18, 2013